From October 30th to November 2nd, 2019, the 50th World Lung Health Conference was held in Hyderabad, India. The conference was hosted by The Union. The theme of this conference is "ENDING THE EMERGENCY: SCIENCE LEADERSHIP ACTION". Public health managers, experts, scholars, R&D and production institutions from different countries and regions gathered here to talk about tuberculosis prevention and control, diagnosis and treatment issues. This conference was held in an unprecedented grand occasion. It was held in India, which is the important task of eliminating tuberculosis in the world.

As a member of The Union, the China Anti-tuberculosis Association came to this conference to learn about international developments and at the same time promote Chinese experts and production companies to integrate with international standards. During the meeting, Chairman Liu Jianjun and Secretary-General Cheng Shiming of the China National Tuberculosis Association invited Mr. Wei Xiaolin, Vice Chairman of The Union, to visit Fosun Pharma’s Gland Pharma in Hyderabad, India, on November 1, 2019, to learn about Indian pharmaceuticals. Industrial development.

The expert group of the Chinese Antituberculosis Association visited Fosun Pharma's pharmaceutical factory in Hyderabad, India

Visiting the preparation production workshop and packaging workshop, the expert group expressed their lament at the rigorous GMP management and quality inspection system of the Indian factory, and praised the Indian pharmaceutical industry for providing patients with high-quality and low-cost medicines. During the exchange, Mr. Yao Fang, the co-chairman of Fosun Pharma, and Mr. Yang Bo, the general manager of Hongqi Pharma, led the Sino-Indian team of Fosun Pharma to communicate with experts, expressing that Fosun Pharma actively promotes business exchanges at home and abroad, and hopes to bring advanced and successful experience to the country. , To promote the improvement of the R&D, production, and quality of Fosun Pharma's China pharmaceutical sector, hoping to bring reliable quality and more economical medicines to Chinese tuberculosis patients. As an important manufacturer of tuberculosis drugs in China, Hongqi Pharmaceutical will rely on Fosun Pharma's high-quality resource background to serve tuberculosis patients in China and serve the cause of tuberculosis prevention and control in China.

During the exchange, Professor Xiaolin Wei suggested that Fosun Pharma should be a helper in the cause of tuberculosis prevention and control from a global perspective; The "Thousand Action" project continues to extend, care for more tuberculosis patients, and take action to eliminate tuberculosis and prevent poverty caused by tuberculosis!